Date: 2014-10-24
Type of information: Production agreement
Compound: undisclosed brand-new radiotherapy product
Company: Eckert & Ziegler (Germany) undisclosed USA based biotech company
Therapeutic area: Cancer - Oncology
Type agreement: manufacturing production
Action mechanism:
Disease: pancreatic cancer
Details: * On October 24, 2014, Eckert & Ziegler Strahlen- und Medizintechnik AG announced that the company is engaging with a USA based biotech company to become a contract manufacturer for a new type of cancer treatment. Therefore Eckert & Ziegler is creating a new production plant for this purpose at its Braunschweig location with financial support provided by the customer. Eckert & Ziegler has several radiopharma production locations in Germany and besides fluorine-18-based radiodiagnostics for nuclear imaging (PET), also distributes the approved product Yttriga®, a precursor to countless radiotherapy products. Globally, Eckert & Ziegler also provides nuclear medicine institutions with synthesis technology and Gallium-68 radionuclide generators.
The cooperation enfolds a brand-new radiotherapy product, currently in development, aimed at treating pancreatic cancer by means of radioimmunotherapy. This form of treatment combines all the benefits of immunotherapy with those offered by radiotherapy. Antibodies transport the source of radiation directly to the cancer cells, enabling the precise deployment of radiation to fight the tumor. Eckert & Ziegler was hand picked as an exclusive contract manufacturer for the clinical phase III trial of the new radiotherapy product in Europe. At its production location in Braunschweig, the radiation specialist couples the antibodies with the radioisotope Yttrium-90 to produce the final active agent.
Financial terms:
Latest news:
